ClinicalTrials.gg
RecruitingNCT07671937INSPIREUpdated Nov 5, 2026

INtegrating Systematic PatIent-Reported Evaluations in Multi-Disciplinary Tumor Boards: The INSPIRE Study

An interventional study of INSPIRE (INtegrating Systematic PatIent-Reported Evaluations) and Capture of patient-reported outcomes in Breast Cancer, Corpus Uteri Cancer and Ovary Cancer, sponsored by University of Alabama at Birmingham. Recruiting at 3 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-05.

Sponsored by University of Alabama at Birmingham · Not applicable, Interventional, and Health services research

How we know

From the registry’s dates

  • Started Oct 2026; still recruiting 1 month later.
Updated Nov 5, 2026Now RecruitingEligibility revised+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
2,748
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 46 studies in Breast Neoplasms by University of Alabama at Birmingham — 7 open to participants now, 11 under way, none of them phase 3. Breast Neoplasms · University of Alabama at Birmingham.

Planned enrollment
Largest of 42
2,748 · median 35
Started
2026
with 2 others
No phase
22 of 46
4 open now
Primary completion
2030-07
later than 10 of 10 live
Registered
46th of 46
by date

Among the 46 studies in Breast Neoplasms by University of Alabama at Birmingham, this one has the largest planned enrollment of the 42 interventional ones that give a count, is one of 3 that started in 2026, is one of 22 with no phase, reaches primary completion later than 10 of the 10 other live ones, and was the 46th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

7 of the 46 studies in Breast Neoplasms by University of Alabama at Birmingham are open now, in 1 country. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Where they have run

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 46 studies in Breast Neoplasms by University of Alabama at Birmingham, or all of them as a file.
02

Study summary

The purpose of the study is to characterize baseline multidisciplinary tumor board (MDTB) context and variability, evaluate the relationship between baseline fitness of patients with cancer and initial treatment recommendations, and assess the impact of the INSPIRE intervention, which involves including electronic patient reported outcomes (ePROs) within MDTB on MDTB discussion content, provider burden, treatment recommended and received, healthcare utilization, and patient-reported outcomes.

Read the detailed description

Study Type/Design This multi-methods study will include two participant groups: patient participants and clinician/provider participants. The patient portion includes an initial prospective observational cohort followed by a randomized controlled trial of the INSPIRE intervention, which involves inclusion of electronic patient-reported outcomes in tumor board discussions. The clinician/provider portion includes audio recording of multidisciplinary tumor board discussions and an optional post-study semi-structured interview with clinicians/providers to understand experiences with the INSPIRE intervention, including feasibility, usefulness, workflow considerations, and implementation challenges.

Patient Participants Patients who agree to participate will complete patient-reported questionnaires at baseline, 3 months, and 6 months. Questionnaires may be completed online by text or email, by phone with responses entered by a research assistant, in person on a tablet, or on paper, based on patient preference. The baseline questionnaire will include questions about health, daily function, quality of life, nutrition, cognition, social support, caregiver support, treatment preferences, and decision-making preferences. At UAB, some of these electronic patient-reported outcomes may already be collected as part of standard clinical care. If a patient has already completed overlapping questionnaires as part of standard care, the patient will not be asked to repeat those questions. Instead, the study team will abstract the relevant information from the electronic medical record or electronic patient-reported outcomes system for research purposes. If the patient has not completed the standard-of-care questionnaires, the patient will complete the study-specific REDCap questionnaire in English or Spanish.

For patients in the initial observational cohort, baseline questionnaire completion may occur within 2 weeks of enrollment. If patients do not complete more than 50% of the questionnaires within 2 weeks, they will be excluded from the study. For patients in the randomized intervention component, completion of the baseline questionnaire will be required before tumor board presentation. The study team will document patients who are unable to complete the questionnaire and the reason. Participants will also complete follow-up questionnaires at approximately 3 months and 6 months after enrollment. These follow-up questionnaires may be completed electronically, by phone, or on paper and will be entered into REDCap. If a patient does not complete a follow-up questionnaire, the research coordinator will make up to three attempts to contact the patient to encourage completion. These contacts may occur by phone, patient portal, or in person during clinic.

The baseline questionnaire is expected to take approximately 40 minutes if the full study questionnaire is completed. If the patient has already completed some electronic patient-reported outcomes as part of standard care, the abbreviated questionnaire is expected to take approximately 20 minutes. The 3-month and 6-month questionnaires are expected to take approximately 10 minutes each. Patients will not be asked to complete any additional clinic visits or study-specific medical procedures.

Use of Patient Questionnaire Information in Tumor Board

After a patient completes the baseline questionnaire, the research coordinator will review the responses and, for patients assigned to the INSPIRE intervention group, create a single PowerPoint slide for tumor board presentation. The slide may include patient frailty or fitness status, frailty components, treatment preferences, decision-making style, and a map showing travel distance from the patient's home to the cancer center. For patients randomized to the intervention group, the slide will be shared during tumor board. The slide will be sent by secure email or secure file transfer to the clinician presenting the case. If the clinician is not available, a research team member or research assistant may present the slide during tumor board. For patients not randomized to the formal INSPIRE presentation group, questionnaire information may still be available to the care team through clinical or study-related workflows, but it will not be formally presented during tumor board as part of the intervention.

Medical Record Review for Patient Participants

Study staff will review patient medical records at baseline to collect information such as demographics, cancer diagnosis and stage, treatment history, prior visits with geriatrics or palliative care, prior cancer history, performance status, medical comorbidities, medications, laboratory results, imaging results, and other information relevant to cancer care. At approximately 6 months, study staff will review the medical record again to collect information about treatment recommendations, treatments received, treatment modifications or delays, complications, health care utilization, palliative care, hospice care, and survival status. Information that cannot be obtained from discrete electronic medical record fields will be entered into REDCap by trained study staff. If a patient withdraws from the study, the study team will ask whether the patient will allow continued medical record review. If the patient declines continued medical record review, the patient's data will be censored at the time of withdrawal.

Tumor Board Recording Procedures

Data from multidisciplinary tumor board presentations on individual patients will be captured by a research coordinator and entered into a REDCap database. This will include HIPPA-protected information, including the MRN. Only the study team will have access to the REDCap database, which will allow them to link individual patient demographics, treatment information, survey responses, and presentation details.

Clinic Notes Review Related to Tumor Board Decision-Making

To understand how treatment decisions are documented after tumor board, the research coordinator will review clinic notes leading up to the initial treatment recommendation. Relevant note content will be copied into a separate document, de-identified, and uploaded for qualitative analysis. The same general coding approach used for tumor board discussions will be applied to clinic note content.

Clinician/Provider Participants

Tumor Board Recording Procedures

Trained research assistants will audio-record eligible tumor board meetings to document discussion content, workflow, and use of patient-reported information in treatment planning. All providers will be informed that tumor board discussions are being recorded for research purposes. If a provider chooses not to participate, that provider's verbal contributions will not be analyzed. Approximately 600 MDTB meetings will be recorded during the study period. These recordings will include eligible tumor board meetings in which enrolled or potentially eligible patient cases are discussed, and we estimate 4-5 patients per tumor board.

All participating tumor boards are expected to occur in hybrid or virtual formats, such as Zoom, Microsoft Teams, or a similar platform. If the tumor board is recorded as part of standard-of-care, the research team will be provided the recording by the clinical team. If the tumor board is not recorded as part of standard of care, the research assistant will attend the meeting and use a recording device to capture the tumor board discussion. The research assistant will also complete standardized data capture forms about the tumor board context and individual patient case presentations, including information such as meeting length, number of cases presented, attendee roles, and discussion flow. The research assistant will not otherwise participate in the clinical discussion, except when presenting the INSPIRE slide if needed.

Field Notes

At each participating site, the research coordinator will capture field notes related to eligible multidisciplinary tumor board meetings. These field notes will document contextual information that may not be fully captured in the audio recording or structured data collection forms, such as meeting format, attendance patterns, workflow issues, timing or agenda changes, interruptions, technical issues, and whether patient-reported information was presented as planned. The research coordinator may also document observations about how the INSPIRE information was incorporated into the tumor board discussion, including who presented the information, whether the information was visible or accessible to tumor board participants, and any notable questions or discussion related to the geriatric assessment, patient preferences, travel distance, or other patient-reported information. Field notes will not be used to evaluate individual clinicians. Field notes will be uploaded into REDCap and stored with other study data.

Clinician Interviews

Clinicians/providers may also be invited to participate in a one-on-one semi-structured interview. The PIs or lead co-investigators will invite clinicians/providers by email. Interviews will be conducted by trained study staff at a time convenient for the participant. Interviews will be conducted remotely using a secure, HIPAA-compliant videoconferencing platform or by telephone, based on participant preference. Interviews are expected to last approximately 30 to 60 minutes. The interviewer will ask about the participant's role in tumor board discussions and experiences with the INSPIRE intervention, including the feasibility and usefulness of incorporating geriatric assessment and patient preference data into tumor board, how the information was presented, factors that supported or limited use of the information in decision-making, provider burden, and recommendations for refinement and future expansion. With participant permission, interviews will be audio-recorded and professionally transcribed or transcribed by study staff for analysis. Clinician/provider participants may decline to participate in an interview, skip any question, or stop the interview at any time. Clinicians/providers who complete an interview will receive $50 for their participation. Payment will be provided after the interview is completed via Greenphire/ClinCard provided in person or via mail at the participants preference.

Site Survey

Annually, site leads for each tumor type will complete a site survey describing basic information about tumor board structure and electronic patient-reported outcome use. This will include information about how tumor boards are organized and how patient-reported information is used in routine care.

03

Conditions studied

  • Breast Cancer
  • Corpus Uteri Cancer
  • Ovary Cancer
  • Pancreas Cancer
  • Other Female Genital Malignant Neoplasms

Keywords

  • PROs
  • Multidiscipinary tumor board
  • INSPIRE intervention
  • Pancreatic Cancer
  • Breast Cancer
  • gynecologic cancers
04

Who can participate

The criteria were revised on the registry on Nov 5, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion/Exclusion Criteria: We will include two populations: (1) patients and (2) clinical team members involved in the MDTB.

Inclusion Criteria:

  • Inclusions Criteria- Patients:

    1. aged 18 years or older;
    2. with suspected or confirmed diagnosis of pancreatic, breast, and gynecologic cancer (all stages) within 8 weeks of diagnosis. This may include diagnosis of a new recurrence. Patients may have had some treatment prior to being seen at a participating institution as long as they are within the 8-week timeframe. Patients may be diagnosed at a participating institution or outside. If there is diagnostic uncertainty and/or patient has not received treatment they will be allowed to participate if they are beyond the 8 weeks of diagnosis.
    3. intention to be treated at a participating institution;
    4. with verbal fluency in English or Spanish; and
    5. scheduled to be discussed at MDTB.
  • Inclusion criteria - Clinicians:

All clinical team members participating in the pancreatic, breast, or gynecologic MDTB at a participating site will be included and have pre-emptively agreed to participation.

Exclusion Criteria:

  • Exclusion criteria - Patients:

Individuals with plans to receive cancer treatment outside the participating institution and inability to speak English or Spanish.

  • Exclusion criteria - Clinician:

Clinicians will retain the opportunity to opt-out of participation, in which case their portions of the discussion will not be included in the analysis; however, this is not anticipated based on pilot data.

05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
2,748 participants (estimated)

Study arms

  • Active comparator
    Group A- Enhanced Usual Care

    Patient-reported outcomes captured; no data presented in any multidisciplinary tumor board. This group is a historical control.

    Behavioral: Capture of patient-reported outcomes

  • Active comparator
    Group B- Enhanced Clinician Awareness

    Patient-reported outcomes (PROs) captured with no personal data presented to multidisciplinary tumor board; other patient's PROs may be presented. This groups is a contemporary control.

    Behavioral: Capture of patient-reported outcomes · Behavioral: Enhanced Clinician Awareness

  • Experimental
    Group C- INSPIRE intervention

    Patient-reported outcomes presented to multidisciplinary tumor board

    Behavioral: INSPIRE (INtegrating Systematic PatIent-Reported Evaluations) · Behavioral: Capture of patient-reported outcomes · Behavioral: Enhanced Clinician Awareness

Interventions

  • BehavioralINSPIRE (INtegrating Systematic PatIent-Reported Evaluations)

    The INSPIRE intervention is the systematic capture and presentation of patient-reported outcomes (geriatric assessment, patient preferences, and distance to care) within multi-disciplinary tumor boards

  • BehavioralCapture of patient-reported outcomes

    Capture of patient-reported outcomes including geriatric assessment and patient preferences

  • BehavioralEnhanced Clinician Awareness

    Inclusion of patients within tumor board that may have patient-reported outcomes

06

What researchers measure

Primary outcomes

  1. Treatment modifications

    Any dose reduction or delay during treatment.

    Time frame: Tumor board presentation to 3 months

Secondary outcomes

  1. Treatment Modifications (2)

    Treatment dose reduction or delay

    Time frame: Tumor board presentation to 6 months

  2. Symptom Experience

    Composite and Individual component scores on Patient-Reported Outcomes Common Terminology Criteria for Adverse Events (PRO-CTCAE) assessment for frequency, severity, and interference of nausea, vomiting, diarrhea, shortness of breath, hair loss, concentration, fatigue, numbness and tingling, pain

    Time frame: Tumor board to 6 months

  3. Symptom Experience (1)

    Composite score and individual components on Patient-Reported Outcomes Common Terminology Criteria for Adverse Events (PRO-CTCAE) assessment for frequency, severity, and interference of nausea, vomiting, diarrhea, shortness of breath, hair loss, concentration, fatigue, numbness and tingling, pain

    Time frame: Tumor board to 3 months

  4. Treatment alignment

    Concordance between (1) treatment received and GA status.

    Time frame: Tumor board presentation to 3 months

  5. Treatment Intensity

    Relative dose intensity, with doses characterized as full or reduced for initial treatment

    Time frame: Tumor board presentation to 3 months

  6. Surgical Complications

    Surgical complications due to cancer surgery using Clavien-Dindo classification for surgical complications

    Time frame: Tumor board presentation to 3 months

  7. Surgical Complications

    Surgical complications related to cancer surgery using Clavien-Dindo classification for surgical complications

    Time frame: Tumor board presentation to 6 months

  8. ER visits - Any (1)

    Any ER visits

    Time frame: Tumor board presentation to 3 months

  9. ER visits - Any (2)

    Any ER visits

    Time frame: Tumor board presentation to 6 months

  10. ER visits - Count (1)

    Number of ER visits

    Time frame: Tumor board presentation to 3 months

  11. ER visits - Count (2)

    Number of ER visits

    Time frame: Tumor board presentation to 6 months

  12. Hospitalization - Any (1)

    Any hospitalization

    Time frame: Tumor board presentation to 3 months

  13. Hospitalization - Any (2)

    Any hospitalization during study period

    Time frame: Tumor board presentation to 6 months

  14. Hospitalization - Count (1)

    Number of hospitalizations

    Time frame: Tumor board presentation to 3 months

  15. Hospitalizations - Count (2)

    Number of hospitalizations in time period

    Time frame: Tumor board presentation to 6 months

  16. ICU - Any (1)

    Any ICU admission during time period

    Time frame: Tumor board presentation to 3 months

  17. ICU - Any (2)

    Any ICU admission during time period

    Time frame: Tumor board presentation to 6 months

  18. ICU - Count (1)

    Number of hospitalization

    Time frame: Tumor board presentation to 3 months

  19. ICU - Count (2)

    Number of ICU admissions

    Time frame: Tumor board presentation to 6 months

  20. Perception of Decision-Making Style

    Control Preferences Scale; Patient perception that the treatment decision was patient-driven, shared, or provider-driven

    Time frame: 3 months from tumor board

  21. Patient Activation (1)

    Patient Activation Measure (PAM) scores, which captured patient knowledge, skill, and confidence in self-management

    Time frame: 3 months from tumor board

  22. Patient Activation (2)

    Patient Activation Measure (PAM) scores that captured patient knowledge, skill, and confidence in self-management

    Time frame: 6 months from tumor board

  23. Treatment Satisfaction (1)

    Score on Treatment Satisfaction Questionnaire for Medication (TSQM)

    Time frame: 3 months from tumor board

  24. Treatment Satisfaction (2)

    Questionnaire for Medication (TSQM) score

    Time frame: 6 months from tumor board

  25. Decision Regret (1)

    Score on Decision Regret Scale

    Time frame: 3 months from tumor board

  26. Decision Regret (2)

    Score on Decision Regret Scale

    Time frame: 6 months from tumor board

  27. Quality of Life (1)

    Score on PROMIS-Global scale

    Time frame: 3 months from tumor board

  28. Quality of Life (2)

    Score on PROMIS-Global scale

    Time frame: 6 months from tumor board

Other outcomes

  1. Tumor board context

    Average number of participants; average number of cases presented; discipline of team members present; role of person typically presenting cases; length of average case; baseline presentation of frailty, comorbid conditions, preferences

    Time frame: During tumor board discussion

  2. Fitness discussed

    Proportion of cases in which clinical team specifically discussed fitness within MDTB

    Time frame: During tumor board and/or initial clinic note

  3. Preferences Discussed

    Proportion of cases in which clinical team specifically discussed preferences within tumor board

    Time frame: during tumor board and/or initial clinic note

  4. Comorbid conditions discussed

    Proportion of cases in which clinical team specifically discussed comorbid conditions within MDTB

    Time frame: during tumor board and/or initial clinic note

07

Study locations

1 of 3 sites recruiting
  • University of Alabama at Birmingham
    Birmingham, Alabama 35294, United States
    Recruiting
    • Gabrielle B Rocque, MD · Contactgrocque@uabmc.edu · (205) 975-2914
    • Margaret A Thomas, MPH · Contactmargaretathomas@uabmc.edu · 2058421632
    • Gabrielle B Rocque, MD · Principal investigator
    • Courtney Williams, DrPH · Sub investigator
    • Nicole Henderson, PhD · Sub investigator
    • Andres Azuero, PhD · Sub investigator
    • Rebecca Arend, MD · Sub investigator
    • Teresa Boitano, MD · Sub investigator
    • Qasim Hussaini, MD · Sub investigator
    • Bart Rose, MD · Sub investigator
    • Joud El Dick, MD · Sub investigator
  • University of California Los Angeles (UCLA)
    Los Angeles, California 90404, United States
    Not yet recruiting
    • Miriam Sillman, MPH · ContactMSilliman@mednet.ucla.edu · 3108253181
    • Emily Martin, MD · Principal investigator
    • Mina Sedrak, MD · Principal investigator
  • University of Oklahoma (OU) Health Campus
    Oklahoma City, Oklahoma 73104, United States
    Not yet recruiting
08

References and documents

Individual participant data

Plan to share: Undecided — We would consider data sharing upon reasonable request with appropriate regulatory approvals and support for data abstraction.

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2026 (actual). Primary completion is estimated for Jul 2030, 45 months after the start.

Of 2,673 non-industry interventional studies with no phase under Breast Neoplasms, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 66. This study's planned 45 months is above that.

Counting every sponsor, half of 2,783 studies reached it within 33 months; a quarter within 15 and three quarters within 66.

Start moved once since we started tracking on Sep 25, 2026: Sep 2026 → Oct 2026, on Oct 7, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 22, 2026
First posted
Jun 26, 2026
StartActual
Oct 2, 2026was Sep 2026
Primary completionEst.
Jul 2030
CompletionEst.
Jul 2031
Last update
Nov 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 7, 2026
Sites
3 sites changed recruiting status (2 now not yet recruiting, 1 now recruiting)
Show 3 sites
  • University of Alabama at Birmingham · Birmingham, United Statesno status→Recruiting
  • University of California Los Angeles (UCLA) · Los Angeles, United Statesno status→Not yet recruiting
  • University of Oklahoma (OU) Health Campus · Oklahoma City, United Statesno status→Not yet recruiting
Oct 7, 2026
Start date
Sep 1, 2026→Oct 2, 2026 (actual)
Oct 7, 2026
Eligibility
1 criterion edited
What changed in the criteria
  • ChangedBefore with suspected or confirmed diagnosis of pancreatic, breast, and gynecologic cancer (all stages) within 8 weeks of diagnosis;Now with suspected or confirmed diagnosis of pancreatic, breast, and gynecologic cancer (all stages) within 8 weeks of diagnosis. This may include diagnosis of a new recurrence. Patients may have had some treatment prior to being seen at a participating institution as long as they are within the 8-week timeframe. Patients may be diagnosed at a participating institution or outside. If there is diagnostic uncertainty and/or patient has not received treatment they will be allowed to participate if they are beyond the 8 weeks of diagnosis.
Nov 5, 2026
Site contacts
Changed at 2 sites. See the sites
Show 2 sites
  • University of California Los Angeles (UCLA) · Los Angeles, United StatesContact none listed→M•••@mednet.ucla.edu · •••3181Contact person changed (no phone or email listed)
  • University of Oklahoma (OU) Health Campus · Oklahoma City, United StatesContact none listed→C•••@ou.edu · •••8778Contact added D•••@ou.edu · •••0111
Oct 7, 2026
Show all 2 updates
  1. Nov 5, 2026
    Eligibility 1 criterion edited
    What changed in the criteria
    • ChangedBefore with suspected or confirmed diagnosis of pancreatic, breast, and gynecologic cancer (all stages) within 8 weeks of diagnosis;Now with suspected or confirmed diagnosis of pancreatic, breast, and gynecologic cancer (all stages) within 8 weeks of diagnosis. This may include diagnosis of a new recurrence. Patients may have had some treatment prior to being seen at a participating institution as long as they are within the 8-week timeframe. Patients may be diagnosed at a participating institution or outside. If there is diagnostic uncertainty and/or patient has not received treatment they will be allowed to participate if they are beyond the 8 weeks of diagnosis.
    + 1 other change: verification date
  2. Oct 7, 2026
    Not yet recruiting→Recruiting
    3 sites changed recruiting status (2 now not yet recruiting, 1 now recruiting)
    Show 3 sites
    • University of Alabama at Birmingham · Birmingham, United Statesno status→Recruiting
    • University of California Los Angeles (UCLA) · Los Angeles, United Statesno status→Not yet recruiting
    • University of Oklahoma (OU) Health Campus · Oklahoma City, United Statesno status→Not yet recruiting
    Start date Sep 1, 2026→Oct 2, 2026 (now actual)
    Site contacts Changed at 2 sites. See the sites
    Show 2 sites
    • University of California Los Angeles (UCLA) · Los Angeles, United StatesContact none listed→M•••@mednet.ucla.edu · •••3181Contact person changed (no phone or email listed)
    • University of Oklahoma (OU) Health Campus · Oklahoma City, United StatesContact none listed→C•••@ou.edu · •••8778Contact added D•••@ou.edu · •••0111
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07671937
Collaborators
University of Oklahoma, University of California, Los Angeles, Canopy Cancer Collective, LLC
Responsible party
Gabrielle Rocque (Associate Professor, University of Alabama at Birmingham) — Principal investigator
First posted
Jun 26, 2026
Start date
Oct 2, 2026
Primary completion
Jul 2030 (estimated)
Completion
Jul 2031 (estimated)
Last update
Nov 5, 2026

Study contacts

Gabrielle B Rocque, MD
Contact
grocque@uabmc.edu
(205) 975-2914
Margaret A Thomas, MPH
Contact
margaretathomas@uabmc.edu
2058421632
Gabrielle B Rocque, MD
principal investigator · The University of Alabama at Birmingham

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion